National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate (Pradaxa®) for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have undergone Total Hip Replacement or Total Knee Surgery.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
 July 2008 September 2008 Reimbursement recommended.

Dabigatran Etexilate (Pradaxa) VTE Prevention summary